Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
NEW YORK–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq:VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
If you own Vanda Pharmaceuticals stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy@glancylaw.com, or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Related news for (VNDA)
- Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
- Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
- Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
- Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
- Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia